Molecular Mechanisms of Resistance to Cancer Therapies

Dear Colleagues,

The persistent challenge of resistance to cancer therapies remains a significant obstacle in achieving durable clinical outcomes across cancer types. Understanding the molecular basis of both innate and acquired therapeutic resistance is critical for improving existing treatments and guiding the development of novel, more effective strategies to improve patient outcomes.

We are pleased to invite you to contribute to a Special Issue that explores “Molecular Mechanisms of Resistance to Cancer Therapies”. This Special Issue aims to highlight recent advances in uncovering the cellular, molecular, and genetic underpinnings of resistance across chemotherapy, targeted therapy, immunotherapy, radiotherapy, and combination approaches.

In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:

• Mechanisms of resistance to chemotherapy, targeted therapies, and immunotherapies;
• Tumor heterogeneity and clonal evolution in therapy resistance;
• Role of the tumor microenvironment and immune evasion;
• Epigenetic and transcriptional reprogramming in resistant cancer cells;
• Non-coding RNAs, including microRNAs and lncRNAs, in modulating resistance;
• Drug efflux, metabolic adaptation, and DNA damage repair pathways;
• Single-cell and spatial transcriptomics approaches to dissect resistance mechanisms;
• Predictive biomarkers and signatures of resistance;
• Strategies to overcome resistance, including combination regimens and novel agents.

We welcome studies spanning in vitro, in vivo, and clinical settings, as well as computational and systems biology approaches that provide novel insights into resistance biology.

Dr. Amancio Carnero
Dr. Rikki A. M. Brown
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.